Huaye Capital has recently been caught in the “radish chapter†event, and the billions of accounts are facing the risk of being unable to recover. Since the announcement of the announcement on September 27, Huaye Capital has fallen for six consecutive days, including the last four days of continuous decline, and fell by 9.73% on October 10. After the stock price opened yesterday, it quickly fell, and the stock accumulated in the past month. It fell 57%.
The crisis was torn from the evening of September 25. On the evening, Huaye Capital announced that the company's subsidiary, Tibet Huashuo Investment Co., Ltd. (hereinafter referred to as “Tibet Huashuoâ€) received the Beijing Jingtailongcheng Investment Management Center (hereinafter referred to as “Jingtailong Cityâ€) on September 25. ) Notice that Tibet Huashuo’s accounts receivable through Jingtailongcheng’s investment were overdue and triggered Tibet Huashuo’s obligation to fulfill the difference. The accumulated overdue amount was 880 million yuan, accounting for 13.06% of the company’s net assets. .
According to the agreement, the hospital should repay the accounts receivable in full before the maturity date, but the hospital only repaid the Jingtai 19 and Jingtai 20 priority principals on time, and did not pay the inferior principal and income. The inferior share of the above-mentioned creditor's rights was all subscribed by Tibet Huashuo Investment. As the hospital did not repay the Jingtai 23 priority principal, Tibet Huashuo supplemented the priority principal of Jingtai 23 as part of the difference. Ten thousand yuan.
And this is just the beginning. Two days later, Huaye Capital announced that the company had appointed lawyers to conduct on-site visits to the debtor (the first, second and third affiliated hospitals of the Army Military Medical University), and presented the relevant “Debt Transfer Agreement†and “Accounts Receivables Claimsâ€. Confirmation and the Confirmation of Receipt issued by the debtor. However, the debtor denied that there was a related debt, and the official seal on the relevant documents was forged, confirming that the above debt was not true.
According to the announcement, the stock of accounts receivable of Huaye Capital was 10.189 billion yuan, all of which were obtained from the same transferor Hengyun Medicine, and the actual controller of Hengyun Medicine is Li Shilin, the second largest shareholder of the company. Huaye Capital said that there is a possibility that Hengyun Medicine is suspected of forging a seal and fiducing the transaction of accounts receivable with the hospital. The company's inventory receivables will face some or all of the risks that cannot be recovered. At present, there is no reasonable explanation for Hengyun Medicine and its actual controller Li Shilin has lost contact. Therefore, this time, Huaye Capital is planted in the "pit" of its own two shareholders.
Huaye Capital’s accounts receivable credit investment business began in 2014. At that time, Huaye Capital, which was originally based on real estate, saw the ceiling of the real estate industry and sought a new direction of transformation. In the same year, the medical and health industry was clearly defined as the company's key investment direction in the future.
In the same year, the company launched a major asset restructuring project, and plans to acquire 100% equity of Chongqing Jieer Medical with a cash of 2.15 billion yuan to add pharmaceutical business and medical services. JAR Healthcare later became the main source of income for the Huaye Capital Healthcare segment.
Li Shilin, the actual controller of Jieer Medical at that time, played a "critical" role in the transformation of Huaye Capital. According to the description of the major asset purchase report, “Li Shilin’s team has accumulated rich channels and experience in the pharmaceutical supply market in Chongqing for many years in the business of pharmaceuticals, reagents, medical devices and consumables.â€
According to the report, in addition to actually controlling Jieer Medical, Li Shilin actually controlled nine pharmaceutical and financial leasing companies including Chongqing Hengyun Medicine. At that time, Li Shilin promised to gradually inject Huaye Capital into the pharmaceutical business business of other enterprises controlled by the other companies within three years after the completion of the equity purchase.
In July 2016, Li Shilin accumulatively increased the holding of 15.33% of Huaye Capital through the actual transfer of Converse Medical, Manchu Medical and Luyi Medical, and became the second largest shareholder of Huaye Capital. At present, Li Shilin’s shares in Huaye Capital have all been pledged.
According to reports, Huaye Capital began to acquire the accounts receivable claims of Hengyun Medicine for the top three hospitals from 2015 onwards. "There has never been a problem before, and the hospital has always paid back on time." Huaye Capital said to the media.
It is reported that in 2015, Huaye Capital proposed to set up a medical financial platform with a total scale of not more than 20 billion yuan for the acquisition of the accounts receivable of the top three hospitals, the establishment of medical supply chain funds, trust plans, and limited partnerships. In 2017, the company's credit investment business confirmed investment income of 615 million yuan, while the company's net profit for the year was 998 million yuan; in the first half of 2018, the company's creditor investment business has achieved investment income of 415 million yuan, accounting for net profit. 42.3%, the company's medical financial platform stock size is about 10.98 billion yuan.
In addition, Huaye Capital currently accounts for 10.189 billion yuan of accounts receivable, and the company uses its own funds to directly purchase accounts receivable at a scale of 2.725 billion yuan; the company participates in the subscription of accounts receivable priority and inferior level. The scale of financial products was 3.718 billion yuan; the scale of other financial institutions participating in the subscription of accounts receivable priority financial products was 3.746 billion yuan.
This means that if some or all of the accounts receivable cannot be recovered, the company will face an unprecedented crisis, and the corresponding financial institutions will follow the “stepping on thunderâ€.
"After the incident, our lawyers and third-party accountants were all in place quickly, and the investigations have already been involved. At the same time, the company is also doing internal control self-examination." The person said that everything is still under investigation and it will take time. At the same time, the company is also working hard to save itself and ensure the normal operation of listed companies. "With so many accounts receivable funds, we believe that we will be able to recover and protect the interests of more than 30,000 investors in listed companies." Huaye Capital said.
On October 9, the company has set up a debt recovery team and an emergency work team, and has reported to the Beijing Public Security Bureau Chaoyang Branch Economic Investigation Brigade, hoping to do its best to recover the accounts.
China Extract Powder For Use As Dietary Supplement Extract Powder, Extract Powder Manufacturer
Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.bio-pharmacies.com